Guideline Recommendations for Diagnosis and Management of Urethritis Without Discharge

Diagnostic Confirmation

The CDC recommends using a Gram stain of urethral secretions that shows ≥5 white blood cells per oil‑immersion field as the preferred rapid diagnostic test because it provides high sensitivity and specificity. 1
When a urethral swab cannot be obtained, the CDC accepts first‑void urine with a positive leukocyte‑esterase test or ≥10 white blood cells per high‑power field on microscopy as an alternative diagnostic specimen. 1
The CDC states that urethral symptoms alone (e.g., dysuria, itching, discomfort) without objective laboratory findings are insufficient to make a diagnosis of urethritis. 1

According to CDC data, Chlamydia trachomatis accounts for 23 %–55 % of nongonococcal urethritis (NGU) cases. 2
The CDC notes that Ureaplasma urealyticum is responsible for 20 %–40 % of NGU cases. 2
Trichomonas vaginalis contributes to 2 %–5 % of NGU cases, per CDC recommendations. 2
The CDC indicates that Mycoplasma genitalium is implicated in 17 %–33 % of NGU cases, but routine testing is not required unless first‑line therapy fails. 1

The CDC advises that patients who are unlikely to return for follow‑up should receive immediate dual therapy for both gonorrhea and chlamydia. 1
The recommended dual regimen includes ceftriaxone 250 mg intramuscularly as a single dose plus doxycycline 100 mg orally twice daily for 7 days (alternative to azithromycin). 1

For laboratory‑confirmed NGU, the CDC recommends azithromycin 1 g orally as a single dose. [1][2]
An alternative CDC‑endorsed regimen is doxycycline 100 mg orally twice daily for 7 days. [1][2]
If macrolides are contraindicated, the CDC lists erythromycin base 500 mg orally four times daily for 7 days as an alternative. [1][2]
Another CDC‑approved option for patients unable to take macrolides or tetracyclines is ofloxacin 300 mg orally twice daily for 7 days. 1

The CDC emphasizes that all sexual partners within the preceding 60 days must be evaluated and treated with the same regimen, regardless of symptoms or test results.
Failure to treat partners is identified by the CDC as the leading cause of persistent or recurrent urethritis. 1

The CDC instructs patients to return for evaluation only if symptoms persist or recur after completing therapy. 1
The CDC states that symptoms alone, without objective signs such as discharge or elevated white‑blood‑cell counts, are insufficient to justify retreatment. 1
Testing for Trichomonas vaginalis and herpes simplex virus is recommended by the CDC in cases of non‑responsive urethritis. 1

The CDC warns that untreated urethritis can lead to epididymitis, Reiter’s syndrome, and transmission to female partners with a risk of pelvic inflammatory disease. 1
Complications are especially associated with Chlamydia trachomatis infection, according to CDC data. [1][2]

The CDC permits deferral of antimicrobial therapy only when no objective signs of urethritis are present and the patient is reliable for follow‑up. 1
For high‑risk individuals (e.g., adolescents, persons with multiple partners) who are unlikely to return, the CDC mandates empiric treatment even in the absence of documented urethritis. 1

The Centers for Disease Control and Prevention recommends treating empirically for both gonorrhea and chlamydia with ceftriaxone 250 mg IM once plus either azithromycin 1 g orally once or doxycycline 100 mg orally twice daily for 7 days when diagnostic tools are unavailable 3, 4
Document urethritis first using criteria such as mucopurulent or purulent urethral discharge on examination, Gram stain showing ≥5 white blood cells per oil immersion field, or positive leukocyte esterase test on first-void urine OR ≥10 white blood cells per high-power field on urine microscopy 4
Test all patients for both N. gonorrhoeae and C. trachomatis using nucleic acid amplification testing (NAAT) on urethral swab or first-void urine 3, 4

Treat for both gonorrhea and nongonococcal urethritis simultaneously with ceftriaxone 250 mg IM as single dose plus either azithromycin 1 g orally as single dose or doxycycline 100 mg orally twice daily for 7 days 4, 5

All sexual partners within the preceding 60 days must be evaluated and treated, regardless of symptoms or test results, as recommended by the Centers for Disease Control and Prevention 4, 6
Both patient and partners must abstain from sexual intercourse for 7 days after treatment initiation or until completion of multi-day regimens, and only after symptoms have completely resolved 4

Instruct patients to return only if symptoms persist or recur after completing therapy, with symptoms alone without objective signs being insufficient for retreatment 4, 7, 6

C. trachomatis is the most frequent cause of nongonococcal urethritis, accounting for 23-55% of cases 3, 7, 6
Mycoplasma genitalium responds better to azithromycin than doxycycline 4

Untreated urethritis leads to epididymitis, Reiter's syndrome, and infection in female partners with risk of pelvic inflammatory disease 7, 6
All patients with sexually transmitted urethritis should receive syphilis serology and HIV counseling/testing at diagnosis, as recommended by the Centers for Disease Control and Prevention 4, 5